Galacto-Oligosaccharides Exert Bifidogenic Effects at Capsule-Compatible Ultra-Low Doses

Area of Science:

• Microbiome research
• Gut health and nutrition
• Prebiotic science

Background:

• Prebiotics promote health by selectively feeding beneficial microorganisms.
• Conventional prebiotic doses often require inconvenient delivery formats.
• This study investigates capsule-compatible galacto-oligosaccharides (GOS) for gut microbiome modulation.

Purpose of the Study:

• To explore the efficacy of capsule-compatible doses of galacto-oligosaccharides (GOS) in modulating the adult gut microbiome.
• To assess the impact of varying GOS doses on microbial composition and short-chain fatty acid (SCFA) production.

Main Methods:

• Utilized the ex vivo SIFR® technology, a clinically validated bioreactor system.
• Assessed the impact of GOS doses (0.5, 0.75, 1.83, and 3.65 g) on the adult gut microbiome (n=8).

Main Results:

• GOS rapidly fermented, significantly increasing beneficial Bifidobacterium species even at the lowest dose.
• Strongly promoted SCFA production, including acetate, butyrate, and propionate.
• Enriched specific Lachnospiraceae species, including Anaerobutyricum hallii, Bariatricus comes, Blautia species, and others, with minimal gas production.

Conclusions:

• Galacto-oligosaccharides (GOS) demonstrate significant prebiotic potential at capsule-compatible doses.
• GOS offers enhanced flexibility for nutritional product formulation and consumer convenience.
• Effective microbiome modulation was observed at lower GOS doses than previously anticipated.